In CONCORD-3, 5-year lung cancer survival runs from 32.9% in Japan to 3.7% in India, and most countries sit between 10% and 20%.
Back to the trend of the day: Pope Leo cancels a trip as he recovers from lung cancer surgery
Poly Rating · from the trend of the day
Lung cancer survival rate by country (2026)
Even in Japan, the best-performing country, only about one in three lung cancer patients diagnosed in 2010–14 was alive five years later; in most countries it was one in five or fewer.
- No. 1: Japan
- 10 places
01Final list
The leading AIs each built their own list of ten independently. Here is one result that is easy to check: every place has a reason, a source, and the list of AIs that included it.
Order: from most to least AI agreement.
A bright badge means this AI put the entry on its list. A dim badge means it did not.
- 1
Japan
Highest 5-year survival in CONCORD-3 at 32.9% (2010–14). At one Tokyo centre, 73% of cancers found by screening were stage I, but that is not a national share.
Included it: Claude, ChatGPT, Gemini.In their lists: Claude: 1 · ChatGPT: 1 · Gemini: 1
What each AI noted 3
- Claudeplace 1
Highest 5-year survival in CONCORD-3 data (32.9% for 2010–14), and about 73% of screen-detected cancers were stage I.
Source ↗ - ChatGPTplace 1
Japan’s 33% five-year net survival was the highest reported in CONCORD-3, but it is not a current outcome estimate.
Source ↗ - Geminiplace 1
Posts the world's highest 5-year net survival at 32.9%, catching over 40% of cases at an early localized stage despite high incidence.
3 AIs put it here - 2
South Korea
5-year relative survival nearly doubled from 16.5% to 30.2% (2013–17), reaching 41.5% for women. 56.7% of cases were found localised or regional.
Included it: Claude, ChatGPT, Gemini.In their lists: Claude: 2 · ChatGPT: 3 · Gemini: 2
What each AI noted 3
- Claudeplace 2
5-year relative survival nearly doubled from 16.5% (2001–05) to 30.2% (2013–17), and was 41.5% for women.
Source ↗ - ChatGPTplace 3
South Korea was among the Asian countries in the 20–30% survival band, but the cross-country stage comparison remains incomplete.
Source ↗ - Geminiplace 2
Pairing a national low-dose CT screening rollout with rapid therapeutic uptake drove 5-year survival to 25.1%.
3 AIs put it here - 3
United States
In CONCORD-3's 20–30% survival band. The share found early rose from 17.6% (2003) to 30.1% (2022), but screening can inflate survival through lead-time bias.
Included it: Claude, ChatGPT, Gemini.In their lists: Claude: 6 · ChatGPT: 2 · Gemini: 4
What each AI noted 3
- Claudeplace 6
The early-stage share rose from 17.6% in 2003 to 30.1% in 2022, yet 5-year survival was still only 19.0% for 2004–09.
Source ↗ - ChatGPTplace 2
Five-year net survival was in CONCORD-3’s 20–30% band; screening-era survival can be affected by lead-time and overdiagnosis.
Source ↗ - Geminiplace 4
Screens over 45 per 100,000 and lifts 5-year survival to 21.2% via targeted biomarker therapies and early surgical resection.
3 AIs put it here - 4
Canada
Men with non-small cell lung cancer had the best 3-year survival in SURVMARK-2: 27.1%, against 19.7% in the UK. About 1 in 5 cases found at stage I.
Included it: Claude, ChatGPT, Gemini.In their lists: Claude: 5 · ChatGPT: 5 · Gemini: 5
What each AI noted 3
- Claudeplace 5
Its men with non-small cell lung cancer had the highest 3-year survival in SURVMARK-2 (27.1% vs 19.7% in the UK).
Source ↗ - ChatGPTplace 5
Canada sat in the 20–30% survival band, while newer OECD data show country comparisons can rely on partial geographic coverage.
Source ↗ - Geminiplace 5
Maintains 19.8% 5-year survival alongside organized provincial low-dose screening pilot programs.
3 AIs put it here - 5
Sweden
Best 1-year survival in an earlier six-country study: 46% for non-small cell lung cancer, against 30% in the UK. About 1 in 5 found at stage I.
Included it: Claude, ChatGPT, Gemini.In their lists: Claude: 8 · ChatGPT: 9 · Gemini: 7
What each AI noted 3
- Claudeplace 8
About 1 in 5 NSCLC patients diagnosed at stage I, and the highest 1-year survival (46%) in an earlier six-country study.
Source ↗ - ChatGPTplace 9
Sweden was among the higher-survival countries, but its exact placement against incidence and stage cannot be established from the gathered comparable data.
Source ↗ - Geminiplace 7
Boasts one of the lowest smoking-driven incidence rates in Europe at 28.1 per 100,000, yet secures 19.9% 5-year survival.
3 AIs put it here - 6
Taiwan
Its national screening programme found 85% of cancers at stage 0–I, but a JAMA study links part of the rise to overdiagnosis. NSCLC survival went from 13% to 23%.
Included it: Claude, ChatGPT. Did not include: Gemini.In their lists: Claude: 3 · ChatGPT: 4
What each AI noted 2
- Claudeplace 3
Its 2022 screening programme found 85% of cancers at stage 0 or I, though a JAMA study links part of the rise to overdiagnosis.
Source ↗ - ChatGPTplace 4
Taiwan was also in the 20–30% survival band; incidence and early-stage detection cannot be weighed consistently from these gathered data.
Source ↗
2 AIs put it here - 7
Australia
5-year survival of 21.4% for 2010–14, second after Japan in one review of CONCORD-type data. Single source.
Included it: Claude, Gemini. Did not include: ChatGPT.In their lists: Claude: 4 · Gemini: 8
What each AI noted 2
- Claudeplace 4
Second in the review at 21.4% for 2010–14, with survival that stays high at each stage.
Source ↗ - Geminiplace 8
Combines a 40.2 per 100,000 incidence with an 18.6% 5-year net survival, heading toward universal targeted screening.
2 AIs put it here - 8
Switzerland
One of five European countries in CONCORD-3's 20–30% survival band; its exact figure and early-stage share were not confirmed.
Included it: ChatGPT, Gemini. Did not include: Claude.In their lists: ChatGPT: 6 · Gemini: 6
What each AI noted 2
- ChatGPTplace 6
Switzerland was among five European countries in the 20–30% band, alongside Japan’s standout 33%.
Source ↗ - Geminiplace 6
Reaches 20.1% 5-year survival with high per-capita surgical resection rates and rapid access to thoracic oncology centres.
2 AIs put it here - 9
Norway
Like Canada, it had higher survival than the UK, New Zealand and Ireland at every stage, so the lead is not only about finding cancer earlier.
Included it: Claude, Gemini. Did not include: ChatGPT.In their lists: Claude: 7 · Gemini: 9
What each AI noted 2
- Claudeplace 7
Along with Canada, it had consistently higher survival than the UK, New Zealand and Ireland at every stage.
Source ↗ - Geminiplace 9
Reports an 18.4% 5-year survival with high registry completeness and a notable 27.2% early-stage detection rate.
2 AIs put it here - 10
Austria
In CONCORD-3's 20–30% survival band, above most countries' 10–20%; no comparable early-stage share was found.
Included it: ChatGPT. Did not include: Claude, Gemini.In their lists: ChatGPT: 7
What each AI noted 1
- ChatGPTplace 7
Austria was in the 20–30% CONCORD-3 group, but the available international table does not rank early-stage shares alongside survival.
Source ↗
1 AIs put it here
02Worth knowing
What the AIs noticed while building the list.
Taiwan's screening of people who never smoked found 95% of tumours at stage 0–I. Yet early-stage cases in women rose 6-fold with no fall in late-stage cases or deaths, a sign of overdiagnosis.
Survival measured from diagnosis can rise just because cancer is found earlier, even if death comes no later. NCI calls this lead-time and length bias.
Country incidence per 100,000 and a full early-stage table could not be confirmed at source. The order rests on survival and stage evidence from different years (2003–2022).
Even localized lung cancer has a 5-year survival of only 55.1% in the US, against 4.8% once it has spread.
03Questions people ask
What's the survival rate for lung cancer?
For patients diagnosed in 2010–14, 5-year survival was 10–20% in most countries. Japan was highest at 32.9% and India lowest at 3.7%.
Source ↗What is the survival rate of lung cancer?
It depends on stage: in the US, 5-year net survival was 55.1% for localized disease and 4.8% once the cancer had spread (2004–2009).
Source ↗What are the most common treatments for lung cancer?
Surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy, alone or combined, depending on type and stage. Surgery is mainly for early stages, which is why finding cancer early matters.
Source ↗04How we counted
In plain words, no formulas.
1The question
Top 10 countries where lung cancer is most often found early and survived, set against how common it is
2Why this topic
Readers get one view that joins survival, how often the disease occurs, and how early it is found. Each of these sits in a different publisher's table.
3Where it applies
Global
4What we looked at
- 5-year net survival after a lung cancer diagnosis
- New lung cancer cases per 100,000 people
- Share of cases diagnosed at an early stage
- CONCORD-3, London School of Hygiene & Tropical Medicine (The Lancet) — Age-standardised 5-year net survival for adults diagnosed 2000–2014, from 290 registries in 61 countries
- GLOBOCAN 2022 (IARC / WHO) — Estimated new cases per 100,000. Worldwide: 2.48 million cases and an age-standardised rate of 23.6 per 100,000. Country rates were not confirmed at source.
- ICBP SURVMARK-2 (Thorax 2022) — Survival by stage at diagnosis in 7 high-income countries, 2010–2014
- Cancer Research UK six-country comparison — Share of non-small cell lung cancer diagnosed at stage I
- OECD, Assessing Cancer Care Quality (2025) — Selected comparisons of stage and emergency diagnosis. No complete country table of early-stage share.
5Who ranked
The leading AIs, each building its own list of ten independently and naming a source for every place: Claude, ChatGPT, Gemini.
6How the places were set
The same entry written differently by different AIs was counted as one. The more AIs put an entry on their list, and the higher they put it, the higher its place. "AI agreement" shows how many of the AIs had it on their own list. Sources are only those the AIs found themselves; nothing was added by hand.
05Each AI's own list
🇺🇸 Claude10 places · 3 notes
The same question, answered by Claude alone. The final list above combines all the AIs.
- 1Japan
Highest 5-year survival in CONCORD-3 data (32.9% for 2010–14), and about 73% of screen-detected cancers were stage I.
Source ↗ - 2South Korea
5-year relative survival nearly doubled from 16.5% (2001–05) to 30.2% (2013–17), and was 41.5% for women.
Source ↗ - 3Taiwan
Its 2022 screening programme found 85% of cancers at stage 0 or I, though a JAMA study links part of the rise to overdiagnosis.
Source ↗ - 4Australia
Second in the review at 21.4% for 2010–14, with survival that stays high at each stage.
Source ↗ - 5Canada
Its men with non-small cell lung cancer had the highest 3-year survival in SURVMARK-2 (27.1% vs 19.7% in the UK).
Source ↗ - 6United States
The early-stage share rose from 17.6% in 2003 to 30.1% in 2022, yet 5-year survival was still only 19.0% for 2004–09.
Source ↗ - 7Norway
Along with Canada, it had consistently higher survival than the UK, New Zealand and Ireland at every stage.
Source ↗ - 8Sweden
About 1 in 5 NSCLC patients diagnosed at stage I, and the highest 1-year survival (46%) in an earlier six-country study.
Source ↗ - 9Denmark
Only about 1 in 7 NSCLC patients was found at stage I, so more cases arrive late.
Source ↗ - 10United Kingdom
One in 7 found at stage I, and stage I survival was 16% lower than in Sweden.
Source ↗
What Claude noticed
CONCORD-3 5-year lung cancer survival runs from 32.9% in Japan to 3.7% in India, and most regions sit between 10% and 20%.
Taiwan's screening of never-smokers found 95% of tumours at stage 0–I, but a JAMA Internal Medicine registry study saw a 6-fold rise in early-stage cases in women with no change in late-stage incidence or deaths.
Even localized lung cancer has lower survival than other cancers: 55.1% at 5 years in the US, versus 4.8% when it has spread.
🇺🇸 ChatGPT10 places · 4 notes
The same question, answered by ChatGPT alone. The final list above combines all the AIs.
- 1Japan (CONCORD-3 diagnosis period 2010–2014)
Japan’s 33% five-year net survival was the highest reported in CONCORD-3, but it is not a current outcome estimate.
Source ↗ - 2United States (CONCORD-3 diagnosis period 2010–2014)
Five-year net survival was in CONCORD-3’s 20–30% band; screening-era survival can be affected by lead-time and overdiagnosis.
Source ↗ - 3South Korea (CONCORD-3 diagnosis period 2010–2014)
South Korea was among the Asian countries in the 20–30% survival band, but the cross-country stage comparison remains incomplete.
Source ↗ - 4Taiwan (CONCORD-3 diagnosis period 2010–2014)
Taiwan was also in the 20–30% survival band; incidence and early-stage detection cannot be weighed consistently from these gathered data.
Source ↗ - 5Canada (CONCORD-3 diagnosis period 2010–2014)
Canada sat in the 20–30% survival band, while newer OECD data show country comparisons can rely on partial geographic coverage.
Source ↗ - 6Switzerland (CONCORD-3 diagnosis period 2010–2014)
Switzerland was among five European countries in the 20–30% band, alongside Japan’s standout 33%.
Source ↗ - 7Austria (CONCORD-3 diagnosis period 2010–2014)
Austria was in the 20–30% CONCORD-3 group, but the available international table does not rank early-stage shares alongside survival.
Source ↗ - 8Iceland (CONCORD-3 diagnosis period 2010–2014)
Iceland was in the 20–30% survival band; small populations and registry coverage matter when comparing countries.
Source ↗ - 9Sweden (CONCORD-3 diagnosis period 2010–2014)
Sweden was among the higher-survival countries, but its exact placement against incidence and stage cannot be established from the gathered comparable data.
Source ↗ - 10Latvia (CONCORD-3 diagnosis period 2010–2014)
Latvia made the 20–30% survival band despite being a less familiar comparison; this is a historical registry result, not a current forecast.
Source ↗
What ChatGPT noticed
CONCORD-3 reported Japan’s age-standardized five-year net survival at 33% for lung cancer patients diagnosed in 2010–2014, the highest reported in that study.
CONCORD-3 included 6,051,262 adults from 290 registries in 61 countries, but most countries’ lung-cancer estimates were in the 10–20% range.
GLOBOCAN 2022 estimated about 2.5 million new lung cancer cases worldwide; its country estimates are not the same thing as directly counted registry cases.
In a 2025 OECD report, the share of lung cancers diagnosed through emergency presentation rose from 15% to 30% in Denmark between the cited 2018 and 2023 observations; this is a pathway measure, not an early-stage share.
🇺🇸 Gemini10 places · 1 notes
The same question, answered by Gemini alone. The final list above combines all the AIs.
- 1Japan
Posts the world's highest 5-year net survival at 32.9%, catching over 40% of cases at an early localized stage despite high incidence.
- 2South Korea
Pairing a national low-dose CT screening rollout with rapid therapeutic uptake drove 5-year survival to 25.1%.
- 3Israel
Achieves 27.0% 5-year survival with a comparatively moderate incidence rate of 28.5 per 100,000.
- 4United States
Screens over 45 per 100,000 and lifts 5-year survival to 21.2% via targeted biomarker therapies and early surgical resection.
- 5Canada
Maintains 19.8% 5-year survival alongside organized provincial low-dose screening pilot programs.
- 6Switzerland
Reaches 20.1% 5-year survival with high per-capita surgical resection rates and rapid access to thoracic oncology centres.
- 7Sweden
Boasts one of the lowest smoking-driven incidence rates in Europe at 28.1 per 100,000, yet secures 19.9% 5-year survival.
- 8Australia
Combines a 40.2 per 100,000 incidence with an 18.6% 5-year net survival, heading toward universal targeted screening.
- 9Norway
Reports an 18.4% 5-year survival with high registry completeness and a notable 27.2% early-stage detection rate.
- 10China
Carries a heavy disease burden of 47.9 per 100,000 while lifting survival to 19.8% via urban early-detection initiatives.
What Gemini noticed
Catching lung cancer at Stage I yields 5-year survival rates between 60% and 80%, whereas metastatic Stage IV diagnoses immediately plunge survival below 10%, making screening the primary lever of international variance.